Pressure BioSciences (OTCMKTS:PBIO) vs. NexGel (NASDAQ:NXGL) Head-To-Head Survey

Pressure BioSciences (OTCMKTS:PBIO) and NexGel (NASDAQ:NXGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Volatility and Risk

Pressure BioSciences has a beta of -0.8, indicating that its share price is 180% less volatile than the S&P 500. Comparatively, NexGel has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares Pressure BioSciences and NexGel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pressure BioSciences	N/A	N/A	N/A
NexGel	-26.27%	-56.90%	-28.42%

Insider and Institutional Ownership

0.0% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by company insiders. Comparatively, 20.6% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Pressure BioSciences and NexGel”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pressure BioSciences	$1.98 million	0.00	-$29.31 million	($0.96)	0.00
NexGel	$11.42 million	0.48	-$3.00 million	($0.38)	-1.70

NexGel has higher revenue and earnings than Pressure BioSciences. NexGel is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Pressure BioSciences and NexGel, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pressure BioSciences	0	0	0	0	0.00
NexGel	1	0	1	0	2.00

NexGel has a consensus target price of $2.00, indicating a potential upside of 209.12%. Given NexGel’s stronger consensus rating and higher probable upside, analysts plainly believe NexGel is more favorable than Pressure BioSciences.

Summary

NexGel beats Pressure BioSciences on 10 of the 14 factors compared between the two stocks.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.